LOS ANGELES–(Business Wire)–DeciBio Consulting, a strategy consulting firm dedicated to the precision medicine space, has launched the Emmes SARS-CoV-2 Testing Database. This database serves as the latest addition to the market intelligence products already under DeciBio Consulting’s umbrella. Such products include the Emmes Infectious Disease Database, the Emmes Oncology Database, BioMAP (immuno-oncology biomarkers), Marketbooks, Dexter, and BioTrack, among others.
The DeciBio Emmes SARS-CoV-2 Testing Database provides data visualization tools and raw data covering coronavirus testing practices in approximately 400 labs in the United States. This data includes diagnostic and serology testing details at hospital, public health, and commercial reference labs, as well as send-out volumes.
DeciBio Consulting’s managing partner David Cavanaugh notes, “Adequate testing is one of the primary ways the country can overcome the pandemic. DeciBio’s SARS-CoV-2 Database aims to provide insights into current testing behavior and trends to measure how the testing industry is responding to the pandemic.”